KIM, Eun Ji,PARK, Hye Jung,YOUN, Sang Jun,PARK, Hyo Ju,HONG, Min Ju,PYO, Hyo Ju,JUNG, Yun Ah,PARK, Hyun Wook,KIM, Yun Jung,SONG, Geun Seog,MOON, Byoung Seok,KANG, Kwi Man
申请号：
HK16100385.5
公开号：
HK1212587A
申请日:
2016.01.14
申请国别(地区):
HK
年份:
2016
代理人:
摘要：
The present invention relates to a formulation of voglibose or a pharmaceutically acceptable salt thereof and metformin or a pharmaceutically acceptable salt thereof which is provided for the reduction, in a substantially equivalent or increased amount compared to single administration of metformin, of HbAlc levels, fasting and postprandial blood glucose levels and postprandial blood glucose variation, or glycemic variability and also the reduction of the frequency of hypoglycemia, cardiovascular complications, and gastrointestinal complications in a patient with no prior experience of anti-diabetes medication or a patient in the early stage of type 2 diabetes showing a HbAlc (%) level of 7 to 11%, and ultimately, is able to effectively treat diabetes in patients in the early stage of type 2 diabetes and to minimize adverse effects, side-effects, and risk of complications.
